Pediatric Stem Cell Transplantation -
Prof. Dr. Peter Bader |
|
| |
> |
Expertise
- Advancement of stem cell therapies in malignant and non-malignant diseases
- Mesenchymal stem cell characterization and therapeutic usage in the treatment of GvHD and induction of tolerance
- Detection of impending relapse after allogeneic stem cell transplantation by molecular techniques
- Development of cellular immunotherapy especially with tumor and leukemia specific T-cells, NK-cells and cytokine induced killer cells.
- Various clinical therapy studies
- Development of clinical trials
|
|
> |
Resources and Abilities
- Flow cytometry , MACS, Elispot, Europium cytotoxicity tests
- Real-Time-PCR, conventional PCR-systems, Reverse transcriptase-PCR, Sequencing
- Cell biology, cell culture and expansion
- Various mouse models
|
> |
Staff
- OA Jan Sörensen, Dr. Andrea Jarisch (Clinical Trials and Patient Care)
- Dr. Hermann Kreyenberg (Clinical Trials, Molecular Biology)
- Dr. Selim Kuçi, Dr. Zyrafete Kuçi (Cell Biology, Cell Culturing)
- Dr. André Willasch (Clinical Trials, Molecular Biology)
- Dr. Gerrit Weber, Dr. Eva Rettinger (T-cell Therapies, Tumor Biology)
|
> |
Links
|
|
| |
| >
|
Publications
- Archambault S, Yoshimi A, Kratz CP, Reising M, Fischer A, Noelke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RBP, Niemeyer CM, Bader P, Loh ML. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia – moving beyond clinical assessment. Blood (2008) 111: 1124-1127.
- Bader P, Willasch A, Niethammer D, Klingebiel T. Haploidentical stem cell transplantation in Childhood. Current Cancer Therapy Reviews (2007) 3: 37-44.
- Willasch A, Hoelle W, Kreyenberg H, Niethammer D, Lang P, Beck JF, Klingebiel T, Bader P. Outcome of allogeneic stem cell transplantation in children with non malignant diseases. Haematologica (2006) 91: 788-794.
- Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, v. Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with ALL after allogeneic SCT – Possible role for preemptive immunotherapy? J Clin Oncol (2004) 22: 1696-1705.
- Bader P, Kreyenberg H, Beck J, Hancock J, Goulden N, Oakhill T, Steward C, Handgretinger R, Niethammer D, Klingebiel T. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post transplant outcome in children with ALL. Leukemia (2002) 16: 1668-1672.
|
|
| |
|
|
